CD46 and age-related macular degeneration: Among the 14 variants, we found four significant variants for early AMD (Table 2): (i) two “tier 2” variants (near PVRL2 and CD46) with experiment-wise significance (P < 0.05/14) in our non-overlapping data and with genome-wide significance (PCombined < 5.0 × 10− 8) in the combined analysis, and (ii) two additional “tier 3” variants (near APOE/TOMM40 and TYR) with experiment-wise significance (P < 0.05/14) in our non-overlapping data.